Last reviewed · How we verify
RAGWEED 12 AMB A 1-U
Ragweed pollen extract allergen immunotherapy that desensitizes the immune system to ragweed allergens through repeated controlled exposure.
Ragweed pollen extract allergen immunotherapy that desensitizes the immune system to ragweed allergens through repeated controlled exposure. Used for Ragweed pollen allergy (allergic rhinitis and/or allergic asthma), Immunotherapy desensitization to ragweed allergens.
At a glance
| Generic name | RAGWEED 12 AMB A 1-U |
|---|---|
| Also known as | RAGWITEK |
| Sponsor | Clinique Spécialisée en Allergies de la Capitale |
| Drug class | Allergen extract immunotherapy |
| Target | Ragweed pollen allergens (Amb a 1 and related epitopes) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | FDA-approved |
Mechanism of action
This is an allergen extract preparation containing ragweed (Ambrosia) pollen antigens used in immunotherapy. It works by gradually inducing immune tolerance to ragweed allergens, reducing allergic responses upon natural exposure. The standardized potency (1-U) allows for controlled dosing in allergy treatment protocols.
Approved indications
- Ragweed pollen allergy (allergic rhinitis and/or allergic asthma)
- Immunotherapy desensitization to ragweed allergens
Common side effects
- Local injection site reactions (erythema, swelling, pruritus)
- Systemic allergic reactions
- Anaphylaxis (rare)
Key clinical trials
- Vestibular Versus Sublingual Route of AIT Tablets (PHASE4)
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) (PHASE3)
- A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751) (PHASE3)
- Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081) (PHASE2)
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED) (PHASE2, PHASE3)
- Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) (PHASE4)
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAGWEED 12 AMB A 1-U CI brief — competitive landscape report
- RAGWEED 12 AMB A 1-U updates RSS · CI watch RSS
- Clinique Spécialisée en Allergies de la Capitale portfolio CI